Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | PLAU | P00749 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2694958 | 0.97 | ALDH1A1 (0.55) | ALDH1A1CYP3A4TSHRTDP1PLAU | |
| Hydrochloric Acid SCHEMBL14763718 | 0.95 | ALDH1A1 (0.54) | ALDH1A1CYP3A4TSHRTDP1PLAU | |
| Sulfuric Acid SCHEMBL21799347 | 0.91 | ALDH1A1 (0.51) | ALDH1A1CYP3A4TSHRTDP1PLAU | |
| Nitric Acid SCHEMBL3858362 | 0.88 | GRIN2D (0.63) | ALDH1A1CYP3A4TSHRTDP1PLAU | |
| SCHEMBL11876448 | 0.84 | GRIN2D (0.66) | ALDH1A1CYP3A4TSHRTDP1PLAU | |
| Nitric Acid SCHEMBL7811356 | 0.81 | ALDH1A1 (0.60) | ALDH1A1CYP3A4TSHRTDP1PLAU | |
| Nitric Acid SCHEMBL3221126 | 0.81 | PLAU (0.41) | ALDH1A1CYP3A4TDP1PLAUCYP2C9 | |
| Nitric Acid SCHEMBL3860675 | 0.81 | TDP1 (0.55) | CYP3A4TDP1PLAUCYP2C9CYP2C19 | |
| Nitric Acid SCHEMBL1587382 | 0.77 | PLAU (0.59) | ALDH1A1TSHRTDP1PLAUGRIN2D | |
| Nitric Acid SCHEMBL1587377 | 0.77 | PLAU (0.59) | ALDH1A1TSHRTDP1PLAUGRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111039921-A | Synthesis process of imatinib and imatinib mesylate | 杭州沧海帆医药科技有限公司 | 2020-04-21 | — | — | CN | claimed |
| EP-1833815-A2 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INSTYTUT FARMACEUTYCZNY (PL) | 2007-09-19 | — | — | EP | claimed |
| WO-2006071130-A2 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INSTYTUT FARMACEUTYCZNY (PL) | 2006-07-06 | — | — | WO | claimed |
| CN-111039921-A | Synthesis process of imatinib and imatinib mesylate | 杭州沧海帆医药科技有限公司 | 2020-04-21 | — | — | CN | disclosed |
| CN-111039921-A | Synthesis process of imatinib and imatinib mesylate | 杭州沧海帆医药科技有限公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-2829538-A1 | Polymorphic form of imatinib mesylate and process for its preparation | Sicor, Inc. (US) | 2015-01-28 | — | — | EP | disclosed |
| US-8466154-B2 | Methods and compositions related to wrapping of dehydrons | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130131076-A1 | METHODS AND COMPOSITIONS RELATED TO WRAPPING OF DEHYDRONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| US-8067421-B2 | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α | SICOR INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2352827-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | Avila Therapeutics, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-7977348-B2 | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α | SICOR INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7232825-B2 | Phenylaminopyrimidine derivatives and methods of use | CHEN GUOQING P | 2007-06-19 | — | — | US | disclosed |
| WO-2006071130-A2 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INSTYTUT FARMACEUTYCZNY (PL) | 2006-07-06 | — | — | WO | disclosed |
| US-20040248918-A1 | Anticancer agents | IL YANG PHARM. CO., LTD. | 2004-12-09 | — | — | US | disclosed |
| WO-2004099186-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | IL YANG PHARM CO., LTD. (KR) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004099187-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | IL YANG PHARM. CO. LTD. (KR) | 2004-11-18 | — | — | WO | disclosed |
| US-20040224967-A1 | Phenylaminopyrimidine derivatives and methods of use | CHEN GUOQING P | 2004-11-11 | — | — | US | disclosed |
| CN-1043531-C | Pyrimidine derivatives and a process for production thereof | NOVATIS AG (CH) | 1999-06-02 | — | — | CN | disclosed |
| US-5521184-A | ANTITUMOR AGENTS; imatinib mesylate | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
| CN-1077713-A | Pyrimidine derivatives and preparation method thereof | CIBA GEIGY AG (CH) | 1993-10-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131076-A1 | METHODS AND COMPOSITIONS RELATED TO WRAPPING OF DEHYDRONS | DKK1, HPN, OSBP2 | ALDH1A1 3889/4885CYP3A4 4096/4885TSHR 4461/4885 |
| US-20040248918-A1 | Anticancer agents | BRDT, CHIA, RNASE1 | ALDH1A1 941/4885CYP3A4 4519/4885TSHR 4475/4885 |
| US-20040224967-A1 | Phenylaminopyrimidine derivatives and methods of use | ABL1, ABL2, LCK | ALDH1A1 331/4885CYP3A4 1774/4885TSHR 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.